Levamisole inactive in treatment of four animal tumours

Nonspecific Macrophage Activation by Systemic Adjuvants

“…results]. Some authors administering these six adjuvants under different experimental conditions have demonstrated inhibitory [2,6,7,14,25], enhancing [2,19], or nil [24] effects on tumor growth. Nevertheless, since no agent which was inactive on macrophages un der our experimental conditions of administration was found to be active, under the same conditions, in preventing tumor growth in vivo, we be lieve that the macrophage activation test can quickly provide information regarding the possible efficiency of an adjuvant in immunotherapy assays.…”

In Vitro Parameters of Cell‐mediated Immune Reactions in Healthy Individuals Following Immune‐stimulation Attempts With Levamisole

“…Studies on tbe immunopotentiatlng ability of levamisole have been carried out in mice, either as investigations on macrophages (7,13), or in experimentally induced tumours (11,12). There seem to be indications of an increased metabolic and phagocjrtic activity in the macrophages after administration of levamisole, whereas its effect as a stimulator of immune defense mechanisms against tumours seems doubtful.…”

“…Levamisole has been found to increase cellmediated immunity, when this was deficient or depressed (15). Levamisole administration reduced the incidence of both primary tumours and lung metastases in the Lewis lung tumour system in mice (12), while Potter et al (11) reported that levamisole was found inactive in the treatment of four other experimentally induced tumours. In some studies an effect of levamisole on antibody production has been shown, but the results are inconsistent (2,11).…”

Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrés des recherches pharmaceutiques

“…A third manner in which to affect interaction with the vasoconstrictor effects innervated by angiotensin II is offered by a direct competitive inhibition of the latter by 'false transmitters'. BUMPUS [305] and other groups [306,307] synthesized various peptides with amino acid sequences that differed slightly from angiotensin. Saralasin (CXLII) showed the expected in vitro angiotensin II antagonism [308] which could subsequently be correlated with antihypertensive efficacy in humans [309].…”

“…Mathematically it can be proved [304] that metabolic systems of the type given by equations (7) to (23), (37) and (38) may follow such a 'limit cycle' under specialized experimental conditions. The glycolytic oscillator, based upon the PFK reaction, has been explored by several investigators [305,306]. Later on, SELKOV [21] pointed out a qualitative extension of his previous theory [12].…”